Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota for transplantation
- Development stage
- Preclinical
- Lead developer
- Rebiotix
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota for transplantation is an investigational live biotherapeutic product developed by OSF HealthCare for the treatment of recurrent Clostridioides difficile infection (CDI). It is administered via endoscopic instillation into the colon. The therapy aims to resolve chronic CDI in patients who have not responded to conventional antimicrobial treatments by restoring a healthy and diverse gut microbial community. This restoration process involves introducing live bacteria from a healthy, screened donor's stool, which competitively excludes C. difficile, breaks the cycle of recurrence, and re-establishes the normal metabolic and immunological functions of the gut microbiome.
- Other names
- fecal microbiota transplantFMTfecal microbiota therapybacteriotherapyintestinal microbiota transplantfecal microbiota-OSF Healthcare System-Clostridioides difficile infection
Beyond the preview
Go deeper on fecal microbiota for transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota for transplantation.